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Abstract
Objectives To validate the gout activity score (GAS) against the gout impact scale in a primary care based gout cohort.
Methods
This was a single-centre cross-sectional study. People with gout who participated in previous research at Academic Rheumatology, University of Nottingham, UK, and consented for participation in future studies were mailed a questionnaire in September 2015. Those returning completed questionnaires were invited to attend for a study visit at which blood was collected and musculoskeletal examination was performed. The Gout Assessment Questionnaire, which contains the gout impact scale (GIS), and short form (SF) 36v2 questionnaires were completed. The GAS 3-step-c score was calculated. Spearman's correlation coefficient was calculated to examine correlation between GAS and SF-36 v2, and GIS.
Statistical analyses were performed using PASW v22.
Results 102 (93% men) of the 150 participants who were mailed a questionnaire attended the study visit. Their mean (SD) age, BMI, serum uric acid and GAS were 67.94 (9.93) years, 29.96 (4.57) kg/m 2 , 5.25 (1.75) mg/dl, and 2.99 (0.74) respectively. There was moderate correlation between GAS and gout concern overall, unmet gout treatment need, and gout concern during an attack components of GIS (r= 0.306 to 0.453), but no to poor correlation between GAS and summary scores and scales of SF-36 v2 (r= -0.090 to -0.251). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 3 Introduction. Gout is the commonest inflammatory arthritis and affects between 1.4 to 2.5% of the general population (1) . It is the only chronic arthritis that can be "cured" by appropriate long-term urate lowering treatment (ULT) (2). Scire and colleagues recently developed the first composite disease activity score (DAS) for gout, the gout activity score (GAS) by employing a Delphi exercise and using a data driven approach (3) . Data from a cohort of Italian gout patients recruited from secondary care rheumatology clinics were used for this purpose, and external validation was carried out in a subset of the cohort (3). GAS is simple to use and correlated moderately with the Health Assessment Questionnaire (HAQ) and Short Form-36 (SF-36) physical component score in this cohort (3) . However, as GAS was developed in a secondary care gout population which may have an overrepresentation of people with difficult to treat and/or severe gout, it is important to examine its relationship with gout specific quality of life (QOL) measures in a primary care gout population. Moreover, the relationship between GAS and gout specific QOL measures, such as the Gout Impact Scale (GIS) (4) and its individual domains (e.g. gout concern overall, gout medication side effects etc.) have not been examined before.
The purpose of this study was to validate GAS in people with gout recruited from primary care. The specific objectives were to examine the correlation between GAS and sub-scales of GIS and summary scores and individual scales of SF-36v2. As GIS is a gout specific QOL instrument, we hypothesized that it will have a stronger correlation with GAS than SF-36v2 which may be influenced by comorbidities. Methods Study design and recruitment. This was a single-centre cross-sectional study. People with gout who participated in gout research at Academic Rheumatology, University of Nottingham, and gave consent to receive information on future studies were mailed a postal questionnaire in September 2015. These participants had participated in a case-control study aimed at developing a biomarker for gout and osteoarthritis (recruited in 2008) (5) , and in an observational study of the effect of physician initiated nurse led treatment of gout on long-term ULT persistence (recruited in 2010-2011) (6) . All participants in the case-control study met the preliminary American Rheumatism Association criteria for gout (7), while all participants in the latter study had crystal proven gout (5, 6) . Their disease and demographic characteristics have been published previously (5, 6). The current study was approved by the University of Nottingham Medical School Ethics Committee.
The postal questionnaire enquired about demographic characteristics, comorbidities, medication use, healthcare use for gout and number of gout attacks in the last year, and included the SF-36v2 and Gout Assessment Questionnaire (GAQ) 2.0. Those who returned completed questionnaires were invited to attend for a study visit at which blood was collected for serum uric acid (SUA) and creatinine measurement.
Participants' height (metres), weight (kilograms) and blood pressure (mm Hg), were measured, and musculoskeletal examination including tophus count was performed.
Calculation of GAS and QOL scores Scire et al developed two simple to use 4-variable GAS scores, the GAS 3-step-c and the GAS 1-step-c with slightly different components (4). Of these, the GAS 3-step-c had the best metric and was externally validated in a sub-set of the KING cohort (4). We calculated GAS 3-step-c using data on self-reported number of gout attacks in the previous 12 months, SUA, patient 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 SF-36v2 a global health related QOL measure and GIS were calculated as described earlier (4, 9) . SF-36v2 has eight scales and two summary scores. All scales and summary scores are scored separately, with higher values indicating better QOL.
GIS evaluates the current impact of gout in five areas, specifically: gout concern overall; gout medication side effects; unmet gout treatment needs; well-being during an attack; and gout concern during an attack. All subscales of GIS are scored separately on a 0 to 100 score [Appendix A, document S2), with higher scores indicating a greater impact (4). Remission GAS score for gout was defined as no gout attacks in the last 12 months, no tophi, serum uric acid <6 mg/dl, and both patient global assessment for gout activity and gout pain ≤2 on a 1-10 scale (10).
Statistical analysis Number (%), mean (standard deviation (SD)), median (interquartile range (IQR)) were used for descriptive purposes. Spearman's correlation coefficient was calculated to examine the correlation between GAS, SF36v2 and GIS as the data were not normally distributed. All statistical analysis were performed using PASW v22. p<0.05 (two tailed) was regarded as statistically significant.
Funding source: This study was supported by Nottingham University Hospitals NHS Trust Charity. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 There was moderate correlation between GAS and gout concern overall, unmet gout treatment need, and gout concern during an attack, and weak correlation with gout medication side effects subscales of GIS with r = 0.383, 0.453, 0.306, 0.227 respectively (Table S1 ). However, there was no correlation between GAS and wellbeing during gout attack subscale of GIS.
There was very weak to weak correlation between the mental component summary scale, and bodily pain, general health, mental health, social functioning domains of SF-36 v2 and GAS (r= -0.196 to -0.251), (Table S2) .
Forty-four participants met the preliminary remission criteria for gout (10) . Their mean (SD) GAS was 2.5 (0.2), and ranged from 1.81 to 2.78. On the contrary, the mean (SD) GAS score for participants not in remission was 3.13 (0.55), and ranged between 2.83 and 3.55. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 7 Discussion Until recently there was no composite measure of disease severity in gout. Consequently, the concept of overall gout severity has remained ambiguous and difficult to measure. Scire et al developed the first global measure of gout activity in 2016 and externally validated it in a hospital cohort (3) . This is the first study to attempt to validate GAS in people with gout recruited from primary care by examining its correlation with GIS. This study found that GAS has a significantly stronger correlation with some components of gout specific QOL measures e.g. gout concern overall, unmet gout treatment need than with a generic overall QOL measure such as SF-36. GAS has the potential of being used as a marker of disease severity, before beginning treatment, and of assessing improvements in gout in a composite way over time. It is easy to measure, can be calculated using web-based calculators just as the disease activity score (DAS) in RA, and provides a measure that will be easy for the patients and their treating doctors to understand. It serves as an important improvement over GIS, which is cumbersome, requires answers on a Likert scale to multiple questions, and cannot be used readily in clinical practice.
This was a well-treated cohort of people with gout and the mean GAS score was low.
However, even in this population, there was moderate correlation between GAS and gout concern overall, gout concern during attack and unmet treatment need subscales of GIS. As expected, GAS, a measure of intercritical gout disease activity did not correlate with wellbeing during gout attack sub-scale of GIS, and further research is required to develop measures that can measure severity of acute gout. Thus, the findings of this study provide construct and external validity to GAS, even in a population with well treated gout. Apart from this, a GAS score of 2.8 was able to differentiate people in remission. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   8 Despite being endorsed by OMERACT for use in gout studies, there was a weaker correlation between GAS and SF36 v2 than between GAS and GIS. Moreover, the physical component score and mental component score of SF36 v2 in this study population correlated less well with GAS than in the study by Scire et al (3) . This may be due to the fact that participants in our study were recruited from the community, and had a significantly lower burden of tophaceous gout and other comorbidities than those participants in the KING study.
Strengths of this study include primary care based recruitment, and systematic assessment for tophus by a single trained research nurse with >10 years' experience of assessing people with gout. We also note some study limitations: this was a cross-sectional study, and we did not directly examine the value of GAS in predicting the occurrence of flare or change ULT dose. Additionally, even though there is a lack of consensus concerning the timeframe over which absence of disease activity defines remission, this study used a single time point, which is not ideal. Also the proportion of gout patients on urate lowering treatment in this study is significantly higher than the proportion on urate lowering treatment in community based studies which may limit the generalisability of our findings.
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We look forward to hearing from you in due course.
Yours sincerely, Dr A Abhishek, PhD
